Phamaceutical company focus on innovative drugs including oncology, neurology and autoimmune diseases.

China based company with focusing on psychiatry.

L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. Founded 38 years ago, L.E.K. employs more than 1,400 professionals around the world. L.E.K. entered China in 1998 and has since become a leading commercial advisor in life sciences and healthcare services practices, covering all aspects of the industry value chain and life cycle. Supported by the Singapore Economic Development Board, L.E.K. established The APAC Life Sciences Centre of Excellence, aiming to provide life sciences companies in APAC with useful insights and practical knowledge, including best practices from other markets around the world. For more information, go to www.lek.com

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.

Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.

Advanced investment bank of China

CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Founded in 2009,Engaged in the R&D，production and sales of peptide related production.